OR WAIT 15 SECS
Eli Lilly added additional affordability options for patients with diabetes who use certain insulin products.
Insulin manufacturers are continuing efforts to provide more cost-savings options to patients with diabetes.
Today, Eli Lilly announced new plans that include 50% lower list prices for certain insulin products that will be available by mid-April, according to a company press release. This will include lower-priced versions of insulin lispro protamine and insulin lispro injectable suspension 100 units/mL (Humalog Mix 75/25 KwikPen) and insulin lispro injection 100 units/mL (Humalog Junior KwikPen).
Lilly initially introduced its first lower-priced insulin, insulin lispro injection 100 units/mL, in May 2019 at a 50% lower list price than the branded version.
Combined, these 3 insulin products comprise of more than 90% of prescriptions written for a mealtime insulin manufactured by Lilly, according to the release. Insulin lispro injectable suspension 100 units/mL, in particular, is one of Lilly’s most prescribed insulin, with approximately 600,000 prescriptions filled in the last 12 months, Lilly said.
The announcements comes after Novo Nordisk also recently introduced its new insulin cost-savings options for patients experiencing difficulties affording their medications. These plans include short-term free, immediate supply for patients in urgent need with a prescription and a $99 purchase program. Novo Nordisk also offers authorized generic versions of their NovoLog and Novolog Mix.
According to Lilly, the lower-priced version of Humalog Mix75/25 will be known as Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 KwikPen (100 units/mL). The lower-priced version of insulin lispro injection 100 units/mL will be known as Insulin Lispro Injection Junior KwikPen (100 units/mL). Both prices will have a list price of $265.20 for a package of 5 KwikPens.
“The cost of insulin at the pharmacy varies dramatically depending on a person’s insurance coverage,” Mike Mason, president, Lilly Diabetes, said in a statement. “These lower-priced insulins may reduce out-of-pocket costs, especially for people in the coverage of Medicare Part D, the uninsured or those with high-deductible insurance plans.”
1. Lilly expands insulin affordability options with lower-priced versions of Humalog Mix 75/25 KwikPen and Humalog Junior KwikPen [news release]. Eli Lilly's website. https://investor.lilly.com/news-releases/news-release-details/lilly-expands-insulin-affordability-options-lower-priced. Accessed January 14, 2020.